NRSN
Neurosense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$6.66
−0.97%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.99
From 52W high−73.80%
Volume6693.00
Market cap$12.62M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$6.99
From 52W high
−73.80%
Volume
6693.00
Market cap
$12.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
P/E (TTM)
—
RSI (14)
37.7
MomentumView details →
1D Return
−0.97%
YTD Return
−56.96%
SummaryUpdated Dec 1, 2025
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Herzliya, Israel. The company went public in December 2021 and focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense is currently advancing its lead drug candidate through clinical trials while building a pipeline of potential treatments for some of the most challenging neurological conditions affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
NeuroSense Therapeutics announced a redesigned, capital-efficient development strategy for its ALS drug PrimeC, including an AI-enabled formulation characterization, a comparative study against edaravone, and an optimized Phase 3 PARAGON trial design, with a New Drug Submission to Health Canada targeted for December 2026.17d agoNeuroSense Therapeutics completed the pre-NDS process with Health Canada for its ALS drug PrimeC, receiving final meeting minutes that align on the planned submission content and structure, and is advancing toward a December 2026 filing.45d agoNeuroSense Therapeutics achieved the primary endpoint in a Phase 2b ALS study with PrimeC, showing statistically significant reduction of TDP-43.83d ago